SeaCrest Wealth Management’s ProQR Therapeutics PRQR Stock Holding History

SeaCrest Wealth Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-71	Closed	-$1K	–	1511
2019 Q1	$1K	Buy	+71	New	+$1.06K	﹤0.01%	2058

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

SeaCrest Wealth Management's PRQR Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of ProQR Therapeutics (PRQR) in Q2 2019, closing a stake of 71 shares — an estimated $1K sold.

SeaCrest Wealth Management first reported a position in PRQR in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 55 funds tracked by Wall St. Rank hold PRQR as of Q2 2019.

SeaCrest Wealth Management reported no remaining ProQR Therapeutics position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 71 ProQR Therapeutics shares in Q2 2019, an estimated $1K.
SeaCrest Wealth Management first reported a position in ProQR Therapeutics in Q1 2019 and held it in 1 quarter.
SeaCrest Wealth Management's ProQR Therapeutics position peaked at $1K in Q1 2019.
55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.